Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.
Epistemonikos ID: fb509fa52ffca422797791c44f554b41b438538a
First added on: May 08, 2024